

2013 (as of 20130312)

Cortés-González JR, Castellanos E, Sandberg K, Eriksson MH, Wiklund P, Carlsson S, Cohn-Cedermark G, Harmenberg U, Gustafsson O, Levitt SH, Lennernäs B, Brandberg Y, Márquez M, Kälkner KM, Nilsson S. *Int J Oncol*. 2013 Jan;42(1):109-17. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.

Arraras JI, Greimel E, Chie WC, Sezer O, Bergenmar M, Costantini A, Young T, Vlastic KK, Velikova G; European Organisation for Research and Treatment of Cancer Quality of Life Group. *Psychooncology*. 2013 Feb;22(2):268-75. Cross-cultural differences in information disclosure evaluated through the EORTC questionnaires.

Hjerpe E, Egyhazi S, Carlson J, Stolt MF, Schedvins K, Johansson H, Shoshan M, Avall-Lundqvist E. *Int J Gynecol Cancer*. 2013 Mar;23(3):448-55. HSP60 Predicts Survival in Advanced Serous Ovarian Cancer.

Patlazhan G, Unukovych D, Pshenisnov K. *Aesthetic Plast Surg*. 2013 Feb 5. DOI: 10.1007/s00266-012-0045-5. Breast Reconstruction and Treatment Algorithm for Patients with Complications after Polyacrylamide Gel Injections: A 10-Year Experience.

Hellman K, Johansson H, Andersson S, Pettersson F, Auer G. *Int J Gynecol Cancer*. 2013 Jan;23(1):41-51. Prognostic significance of cell cycle- and invasion-related molecular markers and genomic instability in primary carcinoma of the vagina.

Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E. *Eur J Cancer*. 2013 Jan;49(1):52-9. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.

2012

Kasparian NA, Bränström R, Chang YM, Affleck P, Aspinwall LG, Tibben A, Azizi E, Baron-Epel O, Battistuzzi L, Bruno W, Chan M, Cuellar F, Debniak T, Pjanova D, Ertmanski S, Figl A, Gonzalez M, Hayward NK, Hocevar M, Kanetsky PA, Leachman S, Bergman W, Heisele O, Palmer J, Peric B, Puig S, Schadendorf D, Gruis NA, Newton-Bishop J, Brandberg Y; Melanoma Genetics Consortium (GenoMEL). *Arch Dermatol*. 2012 Oct;148(10):1142-51. Skin examination behavior: the role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination.

Bränström R, Kasparian NA, Affleck P, Tibben A, Chang YM, Azizi E, Baron-Epel O, Bergman W, Chan M, Davies J, Ingvar C, Kanetsky PA, van Leeuwen E, Olsson H, Gruis NA, Brandberg Y, Newton-Bishop J. *Eur J Cancer*. 2012 Nov;48(16):3052-62. Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma.

Unukovych D, Sandelin K, Liljegren A, Arver B, Wickman M, Johansson H, Brandberg Y. *Eur J Cancer*. 2012 Nov;48(17):3150-6. Contralateral prophylactic mastectomy in breast

cancer patients with a family history: a prospective 2-years follow-up study of health related quality of life, sexuality and body image.

Unukovych D, Sandelin K, Wickman M, Arver B, Johansson H, Brandberg Y, Liljegren A. *Acta Oncol.* 2012 Sep;51(7):934-41. Breast reconstruction in patients with personal and family history of breast cancer undergoing contralateral prophylactic mastectomy, a 10-year experience.

Platten U, Rantala J, Lindblom A, Brandberg Y, Lindgren G, Arver B. *Fam Cancer.* 2012 Sep;11(3):371-9. The use of telephone in genetic counseling versus in-person counseling: a randomized study on counselees' outcome.

Brændengen M, Tveit KM, Hjermstad MJ, Johansson H, Berglund Å, Brandberg Y, Glimelius B. *Eur J Cancer.* 2012 Apr;48(6):813-9. Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study.

Svensson H, Hatschek T, Johansson H, Einbeigi Z, Brandberg Y. *Med Oncol.* 2012 Jun;29(2):432-8. Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.

Sharp L, Finnilä K, Johansson H, Abrahamsson M, Hatschek T, Bergenmar M. *Eur J Oncol Nurs.* 2012 Dec 12. [Epub ahead of print]. No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions - Results from a randomised blinded trial.

Hjermstad MJ, Bergenmar M, Fisher SE, Montel S, Nicolatou-Galitis O, Raber-Durlacher J, Singer S, Verdonck-de Leeuw I, Weis J, Yarom N, Herlofson BB. *Eur J Cancer.* 2012 Sep;48(14):2203-11. The EORTC QLQ-OH17: a supplementary module to the EORTC QLQ-C30 for assessment of oral health and quality of life in cancer patients.

Näsman A, Andersson E, Nordfors C, Grün N, Johansson H, Munck-Wikland E, Massucci G, Dalianis T, Ramqvist T. *Int J Cancer.* 2013 Jan 1;132(1):72-81. MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome.

Näsman A, Romanitan M, Nordfors C, Grün N, Johansson H, Hammarstedt L, Marklund L, Munck-Wikland E, Dalianis T, Ramqvist T. *PLoS One.* 2012;7(6):e38711. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer.

Ståhlbom AK, Johansson H, Liljegren A, von Wachenfeldt A, Arver B. *Fam Cancer.* 2012 Mar;11(1):33-40. Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.

Ahlberg A, Nikolaidis P, Engström T, Gunnarsson K, Johansson H, Sharp L, Laurell G. *Head Neck.* 2012 Jan;34(1):66-72. Morbidity of supraomohyoid and modified radical neck dissection combined with radiotherapy for head and neck cancer: a prospective longitudinal study.

Liljegren A, Gunnarsson P, Landgren BM, Robéus N, Johansson H, Rotstein S. Breast Cancer Res Treat. 2012 Oct;135(3):791-8. Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adjuvant tamoxifen: a randomized controlled trial.

Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Lee A, Barrowdale D, Healey S, Sinilnikova OM, Caligo MA, Loman N, Harbst K, Lindblom A, Arver B, Rosenquist R, Karlsson P, et al. Breast Cancer Res. 2012 Feb 20;14(1):R33. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.

Bergh J, Mariani G, Cardoso F, Liljegren A, Awada A, Viganò L, Huang X, Verkh L, Kern KA, Giorgetti C, Gianni L. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast. 2012 Aug;21(4):507-13. doi: 10.1016/j.breast.2012.01.012. Epub 2012 Feb 14.

Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delalogue S, Huang X, Kern KA, Giorgetti C. J Clin Oncol. 2012 Mar 20;30(9):921-9. doi: 10.1200/JCO.2011.35.7376. Epub 2012 Feb 13. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM, Healey S, Barrowdale D, Lee A, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, Skytte AB, Caligo MA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalin M, Melin B, et al. Hum Mutat. 2012 Apr;33(4):690-702. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

2011

Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b. Eur J Cancer. 2011 Dec 22. [Epub ahead of print]

Hatschek T, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundquist M, Walz TM, Hellström M, Svensson H, Aström G, Brandberg Y, Carstensen J, Fernö M, Bergh J. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. Breast Cancer Res Treat. 2011[Epub ahead of print]

Brandberg Y, Arver B, Johansson H, Wickman M, Sandelin K, Liljegren A. Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: A prospective study. Eur J Surg Oncol. 2011. [Epub ahead of print]

Unukovych D, Khrapach V, Wickman M, Liljegren A, Mishalov V, Patlazhan G, Sandelin K. Polyacrylamide Gel Injections for Breast Augmentation: Management of Complications in 106 Patients, a Multicenter Study. World J Surg. 2011; Apr;36(4):695-701

Arver B, Isaksson K, Atterhem H, Baan A, Bergkvist L, Brandberg Y, Ehrencrona H, Emanuelsson M, Hellborg H, Henriksson K, Karlsson P, Loman N, Lundberg J, Ringberg A, Askmalms MS, Wickman M, Sandelin K. Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. *Ann Surg.* 2011; 253: 1147-54.

Iiristo M, Wiklund T, Wilking N, Bergh J, Brandberg Y. Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels. *Acta Oncol.* 2011; 50: 338-43.

Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H; Nordic Melanoma Cooperative Group. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. *Lancet Oncol.* 2011; 12: 144-52.

Wahlgren T, Levitt S, Kowalski J, Nilsson S, Brandberg Y. Use of the Charlson combined comorbidity index to predict postradiotherapy quality of life for prostate cancer patients. *Int J Radiat Oncol Biol Phys.* 2011; 81: 997-1004.

Wasteson E, Sandelin K, Brandberg Y, Wickman M, Arver B. High satisfaction rate ten years after bilateral prophylactic mastectomy - a longitudinal study. *Eur J Cancer Care.* 2011; 20: 508-13.

Arraras JJ, Greimel E, Chie WC, Sezer O, Bergenmar M, Costantini A, Young T, Vlastic KK, Velikova G; on behalf of the European Organisation for Research and Treatment of Cancer Quality of Life Group. Cross-cultural differences in information disclosure evaluated through the EORTC questionnaires. *Psychooncology.* 2011 [Epub ahead of print]

Sharp L, Johansson H, Landin Y, Moegelin IM, Bergenmar M. Frequency and severity of skin reactions in patients with breast cancer undergoing adjuvant radiotherapy, the usefulness of two assessment instruments - A pilot study. *Eur J Cancer.* 2011 Dec;47(18):2665-72

Arraras JJ, Greimel E, Chie WC, Sezer O, Bergenmar M, Costantini A, Young T, Kuljanic K, Velikova G; European Organisation for Research and Treatment of Cancer Quality of Life Group. Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaire. *Expert Rev Pharmacoecon Outcomes Res.* 2011; 11: 281-6.

Hellbom M, Bergelt C, Bergenmar M, Gijssen B, Loge JH, Rautalahti M, Smaradottir A, Johansen C. Cancer rehabilitation: A Nordic and European perspective. *Acta Oncol.* 2011; 50: 179-86.

Bergenmar M, Johansson H, Wilking N. Levels of knowledge and perceived understanding among participants in cancer clinical trials - factors related to the informed consent procedure. *Clin Trials.* 2011; 8: 77-84.

Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A et al. Common breast cancer susceptibility alleles are associated with tumor subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast*

Cancer Res. 2011 [Epub ahead of print]

Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Putignano AL, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozelik H, Thomassen M, Gerdes AM, Kruse TA, Birk Jensen U, Crüger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B et al.. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet.* 2011; 20: 3304-21.

Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Allavena A, Ottini L, Papi L, Gismondi V, Capra F, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozelik H; OCGN, Thomassen M, Gerdes AM, Kruse TA, Cruger D, Jensen UB, Caligo MA, Olsson H, Kristoffersson U, Lindblom A, Arver B, Karlsson P, Stenmark Askmalm M, Borg A et al. Consortium of Investigators of Modifiers of BRCA1/2. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst.* 2011; 103: 105-16.

Bränström R, Kvillemo P, Moskowitz JT. A Randomized Study of the Effects of Mindfulness Training on Psychological Well-being and Symptoms of Stress in Patients Treated for Cancer at 6-month Follow-up. *Int J Behav Med.* 2011. [Epub ahead of print]

Bränström R, Duncan LG, Moskowitz JT. The association between dispositional mindfulness, psychological well-being, and perceived health in a Swedish population-based sample. *Br J Health Psychol.* 2011; 16: 300-16.

Kvillemo P, Bränström R. Experiences of a mindfulness-based stress-reduction intervention among patients with cancer. *Cancer Nurs.* 2011 Jan-Feb;34(1):24-31.

Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF, Czene K. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. *J Clin Oncol.* 2011; 29: 4014-21.

Osorio A, Milne RL, Alonso R, Pita G, Peterlongo P, Teulé A, Nathanson KL, Domchek SM, Rebbeck T, Lasa A, Konstantopoulou I, Hogervorst FB, Verhoef S, van Dooren MF, Jager A, Ausems MG, Aalfs CM, van Asperen CJ, Vreeswijk M, Waisfisz Q, Van Roozendaal CE, Ligtenberg MJ; HEBON; EMBRACE, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Curzon B, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Adlard J, Eccles D, Ong KR, Douglas F, Downing S, Brewer C, Walker L, Nevanlinna H, Aittomäki K, Couch FJ, Fredericksen Z, Lindor NM, Godwin A, Isaacs C, Caligo MA, Loman N, Jernström H, Barbany-Bustinza G, Liljegren A, Ehrencrona H, Stenmark-Askmalm M et al. Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. *Br J Cancer.* 2011; 104:1356-61.

Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen X, Beesley J, Singer CF, Dressler AC, Gschwantler-Kaulich D, Blum JL, Tung N, Weitzel J, Lynch H, Garber J, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Conroy D, Evans DG, Lalloo F,

Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Selkirk CG, Daly M, Isaacs C, Stoppa-Lyonnet D, Sinilnikova OM, Buecher B, Belotti M, Mazoyer S, Barjhoux L, Verny-Pierre C, Lasset C, Dreyfus H, Pujol P, Collonge-Rame MA; GEMO Study Collaborators, Rookus MA, Verhoef S, Kriege M, Hoogerbrugge N, Ausems MG, van Os TA, Wijnen J, Devilee P, Meijers-Heijboer HE, Blok MJ, Heikkinen T, Nevanlinna H, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Durocher F, Couch FJ, Lindor NM, Wang X, Thomassen M, Domchek S, Nathanson K, Caligo M, Jernström H, Liljegren A, Ehrencrona H, Karlsson P; SWE-BRCA, Ganz PA, Olopade OI, Tomlinson G, Neuhausen S, Antoniou AC, Chenevix-Trench G, Rebbeck TR. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev.* 2011; 20: 1032-8.

Fahlén M, Wallberg B, von Schoultz E, Carlström K, Svensson G, Wilking N, Brandberg Y. Health-related quality of life during hormone therapy after breast cancer: a randomized trial. *Climacteric.* 2011 Feb;14(1):164-70.

Sverrisdottir A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist L, Fornander T. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. *Breast Cancer Res Treat.* 2011; 128: 755-63.

Ahlberg A, Engström T, Nikolaidis P, Gunnarsson K, Johansson H, Sharp L, Laurell G. Early self-care rehabilitation of head and neck cancer patients. *Breast Cancer Res Treat.* 2011; 128: 755-63. *Acta Otolaryngol.* 2011; 131: 552-61.

Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, Johansson H, Lindström L, Bergh J. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. *Breast Cancer Res Treat.* 2011; 125: 553-61.

2010

Svensson H, Einbeigi Z, Johansson H, Hatschek T, Brandberg Y. Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine). *Breast Cancer Res Treat.* 2010; 123: 785-93.

Bränström R, Kasparian NA, Chang YM, Affleck P, Tibben A, Aspinwall LG, Azizi E, Baron-Epel O, Battistuzzi L, Bergman W, Bruno W, Chan M, Cuellar F, Debniak T, Pjanova D, Ertmanski S, Figl A, Gonzalez M, Hayward NK, Hocevar M, Kanetsky PA, Leachman SA, Heisele O, Palmer J, Peric B, Puig S, Schadendorf D, Gruis NA, Newton-Bishop J, Brandberg Y. Predictors of sun protection behaviors and severe sunburn in an international online study. *Cancer Epidemiol Biomarkers Prev.* 2010; 19: 2199-210.

Gahm J, Wickman M, Brandberg Y. Bilateral prophylactic mastectomy in women with inherited risk of breast cancer--prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. *Breast.* 2010; 19: 462-9.

Sackey H, Sandelin K, Frisell J, Wickman M, Brandberg Y. Ductal carcinoma in situ of the breast. Long-term follow-up of health-related quality of life, emotional reactions and body image. *Eur J Surg Oncol.* 2010; 36: 756-62.

Bergenmar M, Månsson-Brahme E, Hansson J, Brandberg Y. Surgical resection margins do not influence health related quality of life or emotional distress in patients with cutaneous melanoma: results of a prospective randomised trial. *Scand J Plast Reconstr Surg Hand Surg.* 2010; 44: 146-55.

Bränström R, Kvillemo P, Brandberg Y, Moskowitz JT. Self-report mindfulness as a mediator of psychological well-being in a stress reduction intervention for cancer patients--a randomized study. *Ann Behav Med.* 2010 ;39: 151-61.

Bränström R, Chang YM, Kasparian N, Affleck P, Tibben A, Aspinwall LG, Azizi E, Baron-Epel O, Battistuzzi L, Bruno W, Chan M, Cuellar F, Debniak T, Pjanova D, Ertmański S, Figl A, Gonzalez M, Hayward NK, Hocevar M, Kanetsky PA, Leaf SL, van Nieuwpoort FA, Heisele O, Palmer J, Peric B, Puig S, Ruffin AD, Schadendorf D, Gruis NA, Brandberg Y, Newton-Bishop J. Melanoma risk factors, perceived threat and intentional tanning: an international online survey. *Eur J Cancer Prev.* 2010; 19: 216-26.

Bränström R, Brandberg Y. Health risk perception, optimistic bias, and personal satisfaction. *Am J Health Behav.* 2010; 34: 197-205.

Bränström R, Penilla C, Pérez-Stable EJ, Muñoz RF. Positive affect and mood management in successful smoking cessation. *Am J Health Behav.* 2010; 34: 553-62.

Bränström R, Duncan LG, Moskowitz JT. The association between dispositional mindfulness, psychological well-being, and perceived health in a Swedish population-based sample. *Br J Health Psychol.* 2010. [Epub ahead of print]

Liljegren A, Gunnarsson P, Landgren BM, Robéus N, Johansson H, Rotstein S. Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adjuvant

tamoxifen: a randomized controlled trial. *Breast Cancer Res Treat.* 2010. [Epub ahead of print]

Walker LC, Fredericksen ZS, Wang X, Tarrell R, Pankratz VS, Lindor NM, Beesley J, Healey S, Chen X; kConFab, Stoppa-Lyonnet D, Tirapo C, Giraud S, Mazoyer S, Muller D, Fricker JP, Delnatte C; GEMO Study Collaborators, Schmutzler RK, Wappenschmidt B, Engel C, Schönbuchner I, Deissler H, Meindl A, Hogervorst FB, Verheus M, Hooning MJ, van den Ouweland AM, Nelen MR, Ausems MG, Aalfs CM, van Asperen CJ, Devilee P, Gerrits MM, Waisfisz Q; HEBON, Szabo CI; ModSQuaD, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Harrington P, Evans DG, Lalloo F, Eeles R, Izatt L, Chu C, Davidson R, Eccles D, Ong KR, Cook J; EMBRACE, Rebbeck T, Nathanson KL, Domchek SM, Singer CF, Gschwantler-Kaulich D, Dressler AC, Pfeiler G, Godwin AK, Heikkinen T, Nevanlinna H, Agnarsson BA, Caligo MA, Olsson H, Kristoffersson U, Liljegren A, Arver B, Karlsson P, Melin B; SWE-BRCA, Sinilnikova OM, McGuffog L, Antoniou AC, Chenevix-Trench G, Spurdle AB, Couch FJ. Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Res.* 2010; 12: R102.

Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, Oliver C, Frost D, Mayes R, Evans DG, Eeles R, Paterson J, Brewer C; Epidemiological Study of Familial Breast Cancer (EMBRACE), McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay M, Michel C, Leroux D, Dreyfus H, Toulas C, Gladiëff L, Uhrhammer N, Bignon YJ, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Preisler-Adams S, Kast K, Deissler H, Sutter C, Gadzicki D, Chenevix-Trench G, Spurdle AB, Chen X, Beesley J; Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab), Olsson H, Kristoffersson U, Ehrencrona H, Liljegren A; Swedish Breast Cancer Study, Sweden (SWE-BRCA), van der Luijt RB, van Os TA, van Leeuwen FE; Hereditary Breast and Ovarian cancer group Netherlands (HEBON), Domchek SM, Rebbeck TR, Nathanson KL, Osorio A, Ramón y Cajal T, Konstantopoulou I, Benítez J, Friedman E, Kaufman B, Laitman Y, Mai PL, Greene MH, Nevanlinna H, Aittomäki K, Szabo CI, Caldes T, Couch FJ, Andrulis IL, Godwin AK, Hamann U, Schmutzler RK; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev.* 2010; 19:2859-68.

Arraras JI, Greimel E, Sezer O, Chie WC, Bergenmar M, Costantini A, Young T, Vlastic KK, Velikova G. An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients. *Eur J Cancer.* 2010; 46: 2726-38.

2009

Von Wachenfeldt A, Brandberg Y, Johansson H, Fornander T. Socioeconomic status and quality of life of women with family history of breast cancer attending an oncogenetic counseling clinic: a comparison with general population. *Acta Oncol.* 2009; 48: 86-92.

Rantala J, Platten U, Lindgren G, Nilsson B, Arver B, Lindblom A, Brandberg Y. Risk perception after genetic counseling in patients with increased risk of cancer. *Hered Cancer Clin Pract.* 2009; 7:15.

Bergenmar M, Hansson J, Brandberg Y. Family members' perceptions of genetic testing for malignant melanoma--a prospective interview study. *Eur J Oncol Nurs.* 2009; 13: 74-80.

Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Healey S; KConFab, Neuhausen SL, Ding YC, Couch FJ, Wang X, Lindor N, Manoukian S, Barile M, Viel A, Tizzoni L, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai P, Rennert G, Lejbkowitz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Weerasooriya N; OCGN, Gerdes AM, Thomassen M, Cruger DG, Caligo MA, Friedman E, Kaufman B, Laitman Y, Cohen S, Kontorovich T, Gershoni-Baruch R, Dagan E, Jernström H, Askmal MS, Arver B, Malmer B; SWE-BRCA, Domchek SM, Nathanson KL, Brunet J, Ramón Y Cajal T, Yannoukakos D, Hamann U; HEBON, Hogervorst FB, Verhoef S, Gómez García EB, Wijnen JT, van den Ouweland A; EMBRACE, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Cook J, Hodgson S, Morrison PJ, Douglas F, Godwin AK; GEMO, Sinilnikova OM, Barjhoux L, Stoppa-Lyonnet D, Moncoutier V, Giraud S, Cassini C, Olivier-Faivre L, Révillion F, Peyrat JP, Muller D, Fricker JP, Lynch HT, John EM, Buys S, Daly M, Hopper JL, Terry MB, Miron A, Yassin Y, Goldgar D; Breast Cancer Family Registry, Singer CF, Gschwantler-Kaulich D, Pfeiler G, Spiess AC, Hansen TV, Johannsson OT, Kirchhoff T, Offit K, Kosarin K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deissler H, Fiebig B, Varon-Mateeva R, Schaefer D, Froster UG, Caldes T, de la Hoya M, McGuffog L, Antoniou AC, Nevanlinna H, Radice P, Benítez J; CMBA. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). *Br J Cancer*. 2009; 101: 2048-54.

Liljegren A, Bergh J, Castany R. Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. *Breast*. 2009; 18: 259-62.

Weber G, Chamorro CI, Granath F, Liljegren A, Zreika S, Saidak Z, Sandstedt B, Rotstein S, Mentaverri R, Sánchez F, Pivarcsi A, Stähle M. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. *Breast Cancer Res*. 2009; 11:R6

Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, Cook M, Evans DG, Eeles R; EMBRACE, Nogues C, Faivre L, Gesta P; GENEPSO, van Leeuwen FE, Ausems MG, Osorio A; GEO-HEBON, Caldes T, Simard J, Lubinski J, Gerdes AM, Olah E, Fürhauser C, Olsson H, Arver B, Radice P, Easton DF, Goldgar DE. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. *Cancer Epidemiol Biomarkers Prev*. 2009; 18: 601-10.

Randén M, Rutqvist LE, Johansson H. Cancer patients without a known primary: incidence and survival trends in Sweden 1960-2007. *Acta Oncol*. 2009; 48: 915-20.

Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. *Breast Cancer Res Treat*. 2009; 117: 561-7.

2008

Johansson B, Brandberg Y, Hellbom M, Persson C, Petersson LM, Berglund G, Glimelius B.

Health-related quality of life and distress in cancer patients: results from a large randomised study. *Br J Cancer*. 2008; 99: 1975-83.

Svensson H, Brandberg Y, Einbeigi Z, Hatschek T, Ahlberg K. Psychological Reactions to Progression of Metastatic Breast Cancer-An Interview Study. *Cancer Nurs*. 2008 Oct 8. [Epub ahead of print]

Bergenmar M, Molin C, Wilking N, Brandberg Y. Knowledge and understanding among cancer patients consenting to participate in clinical trials. *Eur J Cancer*. 2008; 44: 2627-33. 2008; 44: 2627-33.

Brandberg Y, Sandelin K, Erikson S, Jurell G, Liljegren A, Lindblom A, Lindén A, von Wachenfeldt A, Wickman M, Arver B. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. *J Clin Oncol*. 2008 20; 26: 3943-9.

Jayasekara H, Rajapaksa LC, Brandberg Y. Measuring breast cancer-specific health-related quality of life in South Asia: psychometric properties of the Sinhala version of the EORTC QLQ-BR23. *Qual Life Res*. 2008; 17: 927-32.

Arving C, Glimelius B, Brandberg Y. Four weeks of daily assessments of anxiety, depression and activity compared to a point assessment with the Hospital Anxiety and Depression Scale. *Qual Life Res*. 2008; 1: 95-104.

Bränström R, Andréasson S. Regional differences in alcohol consumption, alcohol addiction and drug use among Swedish adults. *Scand J Public Health*. 2008; 36: 493-503.

Bränström R, Sjöström E, Andréasson S. Individual, group and community risk and protective factors for alcohol and drug use among Swedish adolescents. *Eur J Public Health*. 2008; 18:12-8.

Tishelman C, Bergenmar M, Bernhardson BM, Blomberg K, Börjeson S, Foderus H, Leveälähti H, Sahlberg-Blom E, Ternstedt BM. Using undergraduate nursing students as mediators in a knowledge transfer programme for care for patients with advanced cancer. *Eur J Cancer Care (Engl)*. 2008; 17:253-60.

Liljegren A, Barker G, Elliott F, Bertario L, Bisgaard ML, Eccles D, Evans G, Macrae F, Maher E, Lindblom A, Rotstein S, Nilsson B, Mecklin JP, Möslein G, Jass J, Fodde R, Mathers J, Burn J, Bishop DT. Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. *J Clin Oncol*. 2008; 26: 3434-9.

Arriagada R, Rutqvist LE, Johansson H, Kramar A, Rotstein S Predicting distant dissemination in patients with early breast cancer. *Acta Oncol*. 2008; 47: 1113-21.

Sharp L, Johansson H, Fagerström K, Rutqvist LE. Smoking cessation among patients with head and neck cancer: cancer as a 'teachable moment'. *Eur J Cancer Care (Engl)*. 2008; 17: 114-9.

Khoshnoud MR, Fornander T, Johansson H, Rutqvist LE. Long-term pattern of disease

recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen. *Breast Cancer Res Treat.* 2008; 107: 71-8.

2007

Bremberg ER, Brandberg Y, Hising C, Friesland S, Eksborg S. Anemia and quality of life including anemia-related symptoms in patients with solid tumors in clinical practice. *Med Oncol.* 2007; 24: 95-102.

Arving C, Sjöden PO, Bergh J, Hellbom M, Johansson B, Glimelius B, Brandberg Y. Individual psychosocial support for breast cancer patients: a randomized study of nurse versus psychologist interventions and standard care. *Cancer Nurs.* 2007; 30: E10-9.

Wahlgren T, Nilsson S, Lennernäs B, Brandberg Y. Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer. *Int J Radiat Oncol Biol Phys.* 2007; 69: 662-70.

Andréasson S, Sjöström E, Bränström R. A six-community prevention trial to reduce alcohol and drug use-related problems in Sweden: planning and early findings. *Subst Use Misuse.* 2007; 42: 2017-27.

Hansson J, Bergenmar M, Hofer PA, Lundell G, Månsson-Brahme E, Ringborg U, Synnerstad I, Bratel AT, Wennberg AM, Rosdahl I. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program. *J Clin Oncol.* 2007; 25: 2819-24.

Rutqvist LE, Johansson H. Stockholm Breast Cancer Study Group. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. *Acta Oncol.* 2007; 46: 133-45.

Johnsson A, Fornander T, Olsson M, Nystedt M, Johansson H, Rutqvist LE. Factors associated with return to work after breast cancer treatment. *Acta Oncol.* 2007; 46: 90

2006

Bergenmar M, Nylén U, Lidbrink E, Bergh J, Brandberg Y. Improvements in patient satisfaction at an outpatient clinic for patients with breast cancer. *Acta Oncol.* 2006; 45: 550-8.

Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G; Nordic Study Group for Myeloproliferative Disorders. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. *Cancer.* 2006; 106: 2397-405.

Arving C, Sjöden PO, Bergh J, Lindström AT, Wasteson E, Glimelius B, Brandberg Y. Satisfaction, utilisation and perceived benefit of individual psychosocial support for breast cancer patients--a randomised study of nurse versus psychologist interventions. *Patient Educ Couns.* 2006; 62: 235-43.

Petersen MA, Groenvold M, Aaronson N, Blazeby J, Brandberg Y, de Graeff A, Fayers P,

Hammerlid E, Sprangers M, Velikova G, Bjorner JB; European Organisation for Research and Treatment of Cancer Quality of Life Group. Item response theory was used to shorten EORTC QLQ-C30 scales for use in palliative care. *J Clin Epidemiol.* 2006; 59: 36-44.

Azocar F, Branstrom RB. Use of depression education materials to improve treatment compliance of primary care patients. *J Behav Health Serv Res.* 2006; 33: 347-53.

Bränström R, Kristjansson S, Dal H, Rodvall Y. Sun exposure and sunburn among Swedish toddlers. *Eur J Cancer.* 2006; 42: 1441-7.

Bränström R, Kristjansson S, Ullén H. Risk perception, optimistic bias, and readiness to change sun related behaviour. *Eur J Public Health.* 2006; 16: 492-7.

Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC, Peock S, Evans G, Eccles D, Douglas F, Noguès C, Gauthier-Villars M, Chompret A, Van Leeuwen FE, Kluijdt I, Benitez J, Arver B, Olah E, Chang-Claude J; EMBRACE; GENEPSO; GEO-HEBON; IBCCS Collaborators Group. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). *J Natl Cancer Inst.* 2006 Apr 19;98(8):535-44.

Westman B, Bergenmar M, Andersson L. Life, illness and death--existential reflections of a Swedish sample of patients who have undergone curative treatment for breast or prostatic cancer. *Eur J Oncol Nurs.* 2006; 10: 169-76.

He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE, Skog S. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. *Anticancer Res.* 2006; 26 :4753-9.

Rutqvist LE, Johansson H. Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among 'high risk' pre- and postmenopausal breast cancer patients. *Acta Oncol.* 2006; 45: 517-27.

Margolin S, Johansson H, Rutqvist LE, Lindblom A, Fornander T. Family history, and impact on clinical presentation and prognosis, in population-based breast cancer cohort from the Stockholm County. *Fam Cancer.* 2006; 5:309-21.